Results 101 to 110 of about 779,609 (165)

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis - experiences from a single center

open access: yes, 2015
Background: CT-P13 is the first biosimilar monoclonal antibody to infliximab (IFX); it has been approved for the same indications as its IFX counterpart in Hungary.
Nagy, Ferenc   +4 more
core   +2 more sources

Biosimilar CT-P13 in treating ulcerative colitis in the real world [PDF]

open access: yesMinerva Gastroenterology, 2017
Davide G, Ribaldone, Marco, Astegiano
openaire   +3 more sources

Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort

open access: yes, 2018
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has previously been confirmed to be efficacious in inducing mucosal healing in ulcerative colitis (UC) patients.
Palatka Károly   +25 more
core   +1 more source

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. [PDF]

open access: yesJ Crohns Colitis, 2022
Smith PJ   +19 more
europepmc   +1 more source

Clinical Outcomes Following a Switch from Remicade(R) to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study

open access: yes, 2016
Item does not contain fulltextBACKGROUND AND AIMS: The biosimilar of Remicade(R), CT-P13, recently entered the European market. Clinical data on switching from Remicade(R) to CT-P13 in inflammatory bowel disease [IBD] are scarce.
Hoentjen, F.   +6 more
core   +1 more source

Immunomodulators and advanced therapies for maintenance of remission in Crohn’s disease: systematic review and network meta-analysis

open access: yesTherapeutic Advances in Gastroenterology
Background: With the range of options available for the treatment of Crohn’s disease, therapy selection can be challenging in clinical practice. Comparative efficacy data are needed to clarify the relative position of the increasingly complex portfolio ...
Vassiliki Sinopoulou   +7 more
doaj   +1 more source

A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

open access: yesBMC Rheumatology
Background CT-P13 SC, a new subcutaneous (SC) formulation of biosimilar infliximab (IFX), was approved by the European Medicines Agency in 2020 for the treatment of radiographic axial spondyloarthritis (axSpA) in adult patients.
Xenofon Baraliakos   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy